Literature DB >> 32013651

Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis.

Kayoko Tabata1, Naoya Mikita2, Misaki Yasutake1, Ryo Matsumiya1, Katsunori Tanaka1, Sayaka Tani2, Hisako Okuhira2, Masatoshi Jinnin2, Takao Fujii1.   

Abstract

OBJECTIVE: Multiple cytokine network may control the pathogenesis of vasculopathy in patients with systemic sclerosis (SSc). We aimed at comparing angiogenic cytokine profile among SSc patients at various clinical stage.
METHODS: We divided nine patients with anti-centromere antibody (ACA) who were suspected of SSc and diagnosed as having SSc into three groups (group1: pre-clinical stage of SSc, group2: mild/early SSc and group3: typical lcSSc) according to the ACR/EULAR2013 classification criteria or ACR1980 preliminary classification, and serum sample were obtained from them. We evaluated the expression levels of 20 cytokines by membrane array.
RESULTS: Average values of EGF, ENA-78, bFGF, IGF-I, IL-8, MCP-1, TGF-β1, thrombopoietin, VEGF and VEGF-D in group2 were increased compared as those of group1 more than twofold. Statistically significant difference was found in serum levels of IGF-1, RANTES and VEGF between group1 and group2. There was also significant difference in the value of VEGF between group1 and group3. There were mild and significant correlations between serum IGF-1 and RANTES levels (r = 0.721, p = .028).
CONCLUSION: IGF-1, RANTES and VEGF are thought to be involved in the disease development from pre-clinical stage of SSc to early/mild SSc. Thus, these cytokines may be utilized as a biomarker for early diagnosis.

Entities:  

Keywords:  IGF-1; RANTES; Systemic sclerosis; VEGF; angiogenic cytokines

Mesh:

Substances:

Year:  2020        PMID: 32013651     DOI: 10.1080/14397595.2020.1726599

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  4 in total

Review 1.  Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases.

Authors:  Leonardo Martin Calderon; Janet E Pope
Journal:  Front Immunol       Date:  2022-05-05       Impact factor: 8.786

2.  The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Yu-Xia Huang; Fei Li; Dong Liu; Yuan-Yuan Sun; Qin-Hua Zhao; Rong Jiang; Lan Wang; Ping Yuan; Jin-Ming Liu; Yue Wu; Ji Zhang
Journal:  Ann Transl Med       Date:  2021-09

3.  S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study.

Authors:  Paul Balanescu; Eugenia Balanescu; Cristian Baicus; Anca Balanescu
Journal:  J Pers Med       Date:  2021-05-02

4.  Identification of Potential ceRNA Network and Patterns of Immune Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Qiuhong Wu; Yang Liu; Yan Xie; Shixiong Wei; Yi Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.